|
KROS | Keros Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.67 |
| Leverage | 8.79% |
| Market Cap | $ 394.0m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -82.9m |
| Margin | -601.05% |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.